Tickers

1. Composite Trajectory Verdict

Given BBNX's commercial-stage medical device model with high upfront investment in sales force, R&D, and manufacturing, the income statement and cash flow statement carry the most weight for assessing trajectory, as they reflect the core trade-off between revenue growth and the operating losses funding that growth.

Composite Trajectory: Mixed

Revenue growth is strong and accelerating: FY 2025 net sales rose 54% to $100.3M (10-K FY 2025, Consolidated Statements of Operations) and Q2 2026 net sales rose 38% YoY to $32.0M (10-Q Q2 2026, Consolidated Statements of Operations). Gross margin held at 55% for FY 2025 and improved to 59% in Q2 2026 (10-Q Q2 2026, Consolidated Statements of Operations). However, operating losses are widening: FY 2025 loss from operations deepened 58% to $(71.7M) (10-K FY 2025, Consolidated Statements of Operations) and Q2 2026 loss from operations widened 29% YoY to $(25.6M) (10-Q Q2 2026, Consolidated Statements of Operations). Operating cash burn increased in both annual and YTD comparisons (10-K FY 2025, Consolidated Statements of Cash Flows; 10-Q Q2 2026, Consolidated Statements of Cash Flows). The balance sheet shows ample liquidity ($225.2M cash and investments at June 30, 2026 per 10-Q Q2 2026 MD&A) but equity is declining as the accumulated deficit grows to $(415.2M) (10-Q Q2 2026, Consolidated Balance Sheets).

2. Red Flags

• Widening operating losses despite revenue growth: FY 2025 loss from operations $(71.7M) vs $(45.3M) FY 2024 (10-K FY 2025, Consolidated Statements of Operations); Q2 2026 loss from operations $(25.6M) vs $(19.9M) Q2 2025 (10-Q Q2 2026, Consolidated Statements of Operations).
• Operating cash flow deteriorating: Net cash used in operating activities $(50.9M) FY 2025 vs $(48.3M) FY 2024 (10-K FY 2025, Consolidated Statements of Cash Flows); $(38.5M) YTD 2026 vs $(33.6M) YTD 2025 (10-Q Q2 2026, Consolidated Statements of Cash Flows).
• Accumulated deficit accelerating: $(296.7M) Dec 2024 → $(369.9M) Dec 2025 → $(415.2M) June 2026 (10-K FY 2025, Consolidated Balance Sheets; 10-Q Q2 2026, Consolidated Balance Sheets).
• Stock-based compensation surging: Total SBC $6.4M FY 2024 → $16.4M FY 2025 (10-K FY 2025, Consolidated Statements of Operations); quarterly SBC $4.8M Q2 2025 → $7.0M Q2 2026 (10-Q Q2 2026, Selected Quarterly Financial Information).
• Recurring "non-recurring" quality remediation costs: $562K in Q4 2025, $562K in Q1 2026, $62K in Q2 2026 labeled as quality system remediation (10-Q Q2 2026, Adjusted EBITDA reconciliation footnote 1).
• FDA Warning Letter received January 2026 following June 2025 Form 483 inspection, citing Quality Management System, Medical Device Reporting, and Correction and Removals deficiencies (10-Q Q2 2026, MD&A Regulatory Approvals and Actions).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Revenue is growing rapidly: FY 2025 net sales $100.3M (+54% YoY) and Q2 2026 net sales $32.0M (+38% YoY) (10-K FY 2025, 10-Q Q2 2026, Consolidated Statements of Operations). Gross margin is stable to improving: 55% for both FY 2024 and FY 2025, rising to 59% in Q2 2026 and sustained at ~59% for H1 2026 (10-K FY 2025, 10-Q Q2 2026, Consolidated Statements of Operations). However, operating expenses are outpacing gross profit: FY 2025 total OpEx $127.2M (+57% YoY) vs gross profit $55.5M (+55%); Q2 2026 total OpEx $44.5M (+37% YoY) vs gross profit $18.9M (+51%) (10-K FY 2025, 10-Q Q2 2026, Consolidated Statements of Operations). Loss from operations widened in both annual and quarterly YoY comparisons. Net loss widened 34% to $(73.2M) FY 2025 but was flat YTD 2026 at $(45.3M) vs $(45.5M) YTD 2025, helped by absence of warrant fair value charges (10-K FY 2025, 10-Q Q2 2026, Consolidated Statements of Operations).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Operating cash burn is increasing: $(50.9M) FY 2025 vs $(48.3M) FY 2024 (10-K FY 2025, Consolidated Statements of Cash Flows); $(38.5M) YTD 2026 vs $(33.6M) YTD 2025 (10-Q Q2 2026, Consolidated Statements of Cash Flows). Investing cash flows normalized post-IPO: FY 2025 showed $(162.8M) outflow from deploying IPO proceeds into investments; YTD 2026 shows $48.8M inflow as investments mature (10-K FY 2025, 10-Q Q2 2026, Consolidated Statements of Cash Flows). Financing cash flows dropped sharply after IPO: $214.9M FY 2025 (IPO proceeds) vs $2.4M YTD 2026 (stock option exercises only) (10-K FY 2025, 10-Q Q2 2026, Consolidated Statements of Cash Flows). Total cash, equivalents, and investments declined from $264.7M at Dec 2025 to $225.2M at June 2026 per MD&A (10-Q Q2 2026, Liquidity and Capital Resources), though cash and equivalents rose from $31.6M to $44.3M as short-term investments were liquidated (10-K FY 2025, 10-Q Q2 2026, Consolidated Balance Sheets).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Liquidity remains substantial: $225.2M in cash, equivalents, and investments at June 30, 2026 (10-Q Q2 2026, MD&A Liquidity and Capital Resources). No debt outstanding. Total liabilities decreased from $73.6M at Dec 2024 (including $44.9M warrant liabilities) to $41.1M at Dec 2025 to $36.0M at June 2026 as warrants were exercised/converted at IPO (10-K FY 2025, 10-Q Q2 2026, Consolidated Balance Sheets). However, stockholders' equity is declining: $287.6M at Dec 2025 → $256.4M at June 2026, driven by accumulated deficit growing from $(369.9M) to $(415.2M) (10-K FY 2025, 10-Q Q2 2026, Consolidated Balance Sheets). Working capital assets rising: inventories $13.3M → $21.7M → $23.9M; accounts receivable $12.0M → $17.1M → $18.1M (Dec 2024, Dec 2025, June 2026) (10-K FY 2025, 10-Q Q2 2026, Consolidated Balance Sheets).

6. Data Gaps

• Quarterly cash flow statements for individual quarters (only YTD and annual provided)
• Full-year 2026 guidance or updated runway estimate beyond "first half of 2028" (10-Q Q2 2026)
• Detailed breakdown of warranty expense and excess/obsolete inventory reserves by quarter
• Customer concentration metrics for distributors/pharmacy partners
• Unit-level pricing and cost data for iLet vs single-use products by channel
• Capital expenditure forecast for Mint patch pump commercialization
• Specific timeline and cost estimates for T2D pivotal trial and bihormonal Phase 3